Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: an increased risk of angioedema.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  HYPERTENSION

• Publication date

  2009-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/HYPERTENSIONAHA.109.135244PMID 19581503
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated Angioedema

  2009cited by this paper
• Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated Angioedema

  2008cited by this paper
• Angioedema Incidence in US Veterans Initiating Angiotensin-Converting Enzyme Inhibitors

  2008cited by this paper
• National Institute of Diabetes and Digestive and Kidney Diseases

  2008cited by this paper
• Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.

  2007cited by this paper
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  2006cited by this paper
• Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus

  2005cited by this paper
• Incidence and characteristics of angioedema associated with enalapril.

  2005cited by this paper
• Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial.

  2004cited by this paper
• Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms.

  2004cited by this paper
• Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials.

  2004cited by this paper
• Loss of dipeptidylpeptidase IV activity in chronic rhinosinusitis contributes to the neurogenic inflammation induced by substance P in the nasal mucosa

  2002cited by this paper
• Vasopeptidase inhibition and angio-oedema.

  2000cited by this paper
• CD26, let it cut or cut it down.

  1999cited by this paper

• Assessment of Knowledge and General Attitudes of Primary Care Physicians Toward Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Drugs in the Management of Type 2 Diabetes Mellitus in the Qassim Region

  2025cites this paper
• Glycaemic Control in Patients Undergoing Percutaneous Coronary Intervention: What Is the Role for the Novel Antidiabetic Agents? A Comprehensive Review of Basic Science and Clinical Data

  2022cites this paper
• Angioedema associated with dipeptidyl peptidase-IV inhibitors

  2021cites this paper
• Vildagliptin: a new treatment for type 2 diabetes

  2018cites this paper
• Selective separation and characterisation of dualACEandDPP‐IVinhibitory peptides from rainbow trout (Oncorhynchus mykiss) protein hydrolysates

  2018cites this paper
• Angioedema in Australia: hospital admission rates and fatalities, 2000–2013

  2018cites this paper
• Le cas clinique du mois. Embolie pulmonaire compliquée d’un œdème laryngé angioneurotique.

  2017cites this paper
• Non‐insulin anti‐diabetic drugs: An update on pharmacological interactions

  2017cites this paper
• Sitagliptin–Moringa oleifera coadministration did not delay the progression nor ameliorated functional and morphological anomalies in alloxan-induced diabetic nephropathy

  2017cites this paper
• WKY preglomerular vascular smooth muscle cells

  2016cites this paper
• Drug-induced angioedema: an update on new cases and new drugs

  2016cites this paper
• “Nuts and Bolts” of Laboratory Evaluation of Angioedema

  2016cites this paper
• Distinct Conditions Support a Novel Classification for Bradykinin-Mediated Angio-Oedema

  2015cites this paper
• The opioid effects of gluten exorphins: asymptomatic celiac disease

  2015cites this paper
• DPP-4 inhibitors: a patent review (2012 – 2014)

  2015cites this paper
• Strategies of Hyperglycemia Management among Patients with Diabetic Nephropathy, Renal Impairment, Hypertension and Lipid Disorders

  2015cites this paper
• Dipeptidyl peptidase‐4 inhibitors: Multitarget drugs, not only antidiabetes drugs (D ipeptidyl peptidase ‐4抑制剂：多靶点药物，不仅仅是降糖药)

  2014cites this paper
• Factors affecting the development of adverse drug reactions (Review article).

  2014cites this paper
• Vascular Origin of Vildagliptin-induced Skin Effects in Cynomolgus Monkeys

  2014cites this paper
• Factors affecting the development of adverse drug reactions (Review article)

  2014cites this paper
• Peripheral Sympathetic System and Neuropeptide Y Vascular Origin of Vildagliptin-induced Skin Effects in Cynomolgus Monkeys : Pathomechanistic Role of

  2014cites this paper
• Role of RACK1 in the differential proliferative effects of neuropeptide Y(1-36) and peptide YY(1-36) in SHR vs. WKY preglomerular vascular smooth muscle cells.

  2013cites this paper
• Drug-induced angioedema: experience of Italian emergency departments

  2013cites this paper
• Renin-angiotensin system inhibitors and angioedema: anesthetic implications.

  2012cites this paper
• Selective inhibition of dipeptidyl peptidase 4 by targeting a substrate-specific secondary binding site

  2011cites this paper
• Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes.

  2011cites this paper
• Selection and Dosing of Medications for Management of Diabetes in Patients with Advanced Kidney Disease

  2010cites this paper
• Dipeptidyl peptidase IV inhibition alters the hemodynamic response to angiotensin-converting enzyme inhibition in humans with the metabolic syndrome.

  2010cites this paper
• Association of angiotensin‐converting enzyme inhibitor‐associated angioedema with transplant and immunosuppressant use

  2010cites this paper
• Hypertension: Angio-œdème sous inhibition de l'enzyme de conversion de l'angiotensine et de la dipeptidyl-peptidase-4

  2010cites this paper
• Dipeptidylpeptidase-4 Inhibitors (Gliptins)

  2010cites this paper
• Sitagliptin augments angiotensin II‐induced renal vasoconstriction in kidneys from rats with metabolic syndrome

  2010cites this paper